Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (10,830)	$ (5,549)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,553	5,293
Impairment expense	2,284	0
Amortization of operating lease right-of-use assets	349	395
Amortization of deferred financing costs and debt discount	140	157
Change in allowance for credit losses	(110)	107
Stock-based compensation expense	1,303	1,466
Loss on debt extinguishment	909	0
Loss on disposal of property and equipment	72	52
Deferred income taxes	(120)	40
Changes in operating assets and liabilities:
Accounts receivable	141	(1,145)
Inventories	689	(1,340)
Prepaid expenses and other assets	246	(111)
Accounts payable	(100)	603
Accrued expenses and other liabilities	(197)	229
Deferred revenues	(472)	(644)
Operating lease liabilities	(376)	(477)
Net cash used in operating activities	(519)	(924)
Cash flows from investing activities:
Purchase of property and equipment	(5,019)	(3,736)
Cash paid in connection with TheraClear asset acquisition	0	(631)
Net cash used in investing activities	(5,019)	(4,367)
Cash flows from financing activities:
Proceeds from long-term debt	7,000	0
Payment of deferred financing costs	(97)	0
Payment of contingent consideration	(42)	(500)
Net cash provided by (used in) financing activities	6,861	(500)
Net increase (decrease) in cash, cash equivalents and restricted cash	1,323	(5,791)
Cash, cash equivalents and restricted cash at beginning of year	6,795	12,586
Cash, cash equivalents and restricted cash at end of year	8,118	6,795
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	1,415	744
Cash paid during the year for income taxes	22	19
Supplemental schedule of non-cash operating, investing and financing activities:
Modification of common stock warrants	384	0
Transfer of property and equipment to inventories	267	463
Change in intangible assets and fair value of contingent consideration	7,374	0
Accrued exit fee recorded as debt discount	450	0
Accrued payment of contingent consideration	18	0
Inventories acquired in connection with TheraClear asset acquisition	0	71
Intangible assets acquired in connection with TheraClear asset acquisition	0	10,182
Contingent consideration issued in connection with TheraClear asset	0	9,122
Common stock issued in connection with TheraClear asset acquisition	0	500
Change in operating lease right-of-use assets and liabilities due to new and amended leases	$ 0	$ 732